Nicholas Hornstein/X
Jan 26, 2025, 15:37
Nicholas Hornstein: HER2 blockade in resectable gastric cancer without benefit
Nicholas Hornstein, Assistant Professor of Medical Oncology at Northwell Health, shared a post on X:
“HER2 blockade in resectable gastric cancer without benefit.
Addition of Herceptin +/- pertuzumab to FLOT did not have significant benefit for resectable gastric patients.
EORTC-1203
Notable response rate improvement adding trastuzumab to Ctx (23 vs 37 %)
Negative study, but more to come for anti-her2 therapies in gastric.”
More posts featuring Nicholas Hornstein.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38